Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Stoke Therapeutics Inc
(NQ:
STOK
)
14.03
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Stoke Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Why Stoke Therapeutics Is Trading Lower Today?
July 25, 2023
Stoke Therapeutics Inc (NASDAQ: STOK) shares are trading lower after the company released new safety & efficacy data from STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
July 25, 2023
On Tuesday, 56 companies set new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 25, 2023
Via
Benzinga
What 8 Analyst Ratings Have To Say About Stoke Therapeutics
June 26, 2023
Via
Benzinga
Analyst Expectations for Stoke Therapeutics's Future
June 08, 2023
Via
Benzinga
Analyst Ratings for Stoke Therapeutics
June 08, 2023
Via
Benzinga
12 Analysts Have This to Say About Stoke Therapeutics
May 23, 2023
Via
Benzinga
Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome
July 25, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Scholastic, Matson, Digital World Acquisition And Other Big Stocks Moving Higher On Friday
July 21, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 90 points on Friday. Here are some big stocks recording gains in today’s session. Digital World Acquisition Corp. (NASDAQ: DWAC) climbed 69%...
Via
Benzinga
Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome
July 21, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Where Stoke Therapeutics Stands With Analysts
May 23, 2023
Via
Benzinga
Stoke Therapeutics: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 24, 2023
Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 23, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 21, 2023
Via
Benzinga
What 7 Analyst Ratings Have To Say About Stoke Therapeutics
April 26, 2023
Via
Benzinga
Credit Suisse Maintains Outperform Rating for Stoke Therapeutics: Here's What You Need To Know
March 07, 2023
Via
Benzinga
6 Analysts Have This to Say About Stoke Therapeutics
March 07, 2023
Via
Benzinga
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 16, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Adobe And 2 Other Stocks Insiders Are Selling
May 04, 2023
The S&P 500 closed lower on Wednesday after the Fed increased rates by 25 basis points, as widely expected. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 04, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the BofA Securities Health Care Conference
May 03, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Expert Ratings for Stoke Therapeutics
January 11, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
May 01, 2023
Via
Benzinga
Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom
April 25, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
March 15, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 06, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Participate at Upcoming March Investor Conferences
February 27, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023
January 09, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.